The ATTR-CM drug race almost got another contender, but AstraZeneca and Ionis’ Wainua unexpected Phase 3 trial failure might have actually simplified the field. Initially intended to support FDA approval, the Phase 3 CARDIO-TTRansform study enrolled 1,432 patients and randomized them to Wainua or placebo plus standard of care, with results showing that… The most […] The post CARDIO-TTRansform and The Future of ATTR-CM Drugs appeared first on Cardiac Wire .